Published research on Niclosamide
4 peer-reviewed publications on Niclosamide in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Clinical trial
In nine men with metastatic castration-resistant prostate cancer, a reformulated oral niclosamide combined with abiraterone and prednisone produced no dose-limiting toxicities, achieved plasma levels above the preclinical threshold, and five of eight evaluable patients had a PSA response.
- Clinical trial
Oral niclosamide could not be escalated beyond the highest tested dose because of dose-limiting gastrointestinal toxicity, plasma concentrations were not consistently above the preclinical therapeutic threshold, no PSA declines were observed, and the study was closed for futility.
- In vivo
Niclosamide inhibited Wnt/beta-catenin signalling and proliferation in human colorectal cancer cell lines and patient-derived cells regardless of APC mutation status, and orally administered niclosamide was well tolerated and led to tumour control in colorectal cancer xenografts.
- In vivo
Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer
Niclosamide reduced S100A4 expression, migration, invasion and colony formation in colon cancer cells in vitro and reduced liver metastasis formation and increased overall survival in a xenograft mouse model of colon cancer.
Niclosamide in the catalog (specifications, pack sizes, Certificate of Analysis)